Review



pbabe puro egfr wild-type  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Addgene inc pbabe puro egfr wild-type
    A, Diagram of domain architecture of <t>EGFR,</t> showing heterodimerization between EGFR and a binding partner such as Her2. Yellow star indicates approximate site of the common oncogenic L858 mutation, red star indicates approximate site of the N361 glycosylation site, green indicates ligands such as EGF or AREG that bind to EGFR to induce dimerization. B, Percentage of fluorescent cells from flow cytometry of MCF10A cells that were labeled with anti-EGFR antibody conjugated to Alexa-Fluor 488, or empty <t>puro-IRES-eGFP</t> vector as the stably fluorescent positive control which is not labeled by fluorescent antibody. Cells used were parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A. C, Representative immunofluorescent microscopy images of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A, stained for EGFR, vimentin, ATP1A1, or DAPI.
    Pbabe Puro Egfr Wild Type, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbabe puro egfr wild-type/product/Addgene inc
    Average 90 stars, based on 1 article reviews
    pbabe puro egfr wild-type - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function"

    Article Title: Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function

    Journal: bioRxiv

    doi: 10.1101/2024.07.12.603279

    A, Diagram of domain architecture of EGFR, showing heterodimerization between EGFR and a binding partner such as Her2. Yellow star indicates approximate site of the common oncogenic L858 mutation, red star indicates approximate site of the N361 glycosylation site, green indicates ligands such as EGF or AREG that bind to EGFR to induce dimerization. B, Percentage of fluorescent cells from flow cytometry of MCF10A cells that were labeled with anti-EGFR antibody conjugated to Alexa-Fluor 488, or empty puro-IRES-eGFP vector as the stably fluorescent positive control which is not labeled by fluorescent antibody. Cells used were parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A. C, Representative immunofluorescent microscopy images of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A, stained for EGFR, vimentin, ATP1A1, or DAPI.
    Figure Legend Snippet: A, Diagram of domain architecture of EGFR, showing heterodimerization between EGFR and a binding partner such as Her2. Yellow star indicates approximate site of the common oncogenic L858 mutation, red star indicates approximate site of the N361 glycosylation site, green indicates ligands such as EGF or AREG that bind to EGFR to induce dimerization. B, Percentage of fluorescent cells from flow cytometry of MCF10A cells that were labeled with anti-EGFR antibody conjugated to Alexa-Fluor 488, or empty puro-IRES-eGFP vector as the stably fluorescent positive control which is not labeled by fluorescent antibody. Cells used were parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A. C, Representative immunofluorescent microscopy images of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A, stained for EGFR, vimentin, ATP1A1, or DAPI.

    Techniques Used: Binding Assay, Mutagenesis, Glycoproteomics, Flow Cytometry, Labeling, Plasmid Preparation, Stable Transfection, Positive Control, Microscopy, Staining

    A, Time course of relative viability of in parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A, measured by Cell-Titer Glo luciferase assay (CTG) in stimulated media with 20 ng/mL of EGF. B, Dose course of relative viability of MCF10A cells overexpressing the indicated constructs after stimulation by EGF for 72 hours, measured by CTG. C, Dose course of relative viability of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A upon stimulation by AREG for 72 hours, both measured by CTG; ns = not significant, * p < 0.05; *** p < 0.001, n = 3; D, Immunoblots of whole cell lysates of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A stimulated with an additional 20 ng/mL of EGF for 15 minutes.
    Figure Legend Snippet: A, Time course of relative viability of in parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A, measured by Cell-Titer Glo luciferase assay (CTG) in stimulated media with 20 ng/mL of EGF. B, Dose course of relative viability of MCF10A cells overexpressing the indicated constructs after stimulation by EGF for 72 hours, measured by CTG. C, Dose course of relative viability of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A upon stimulation by AREG for 72 hours, both measured by CTG; ns = not significant, * p < 0.05; *** p < 0.001, n = 3; D, Immunoblots of whole cell lysates of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A stimulated with an additional 20 ng/mL of EGF for 15 minutes.

    Techniques Used: Luciferase, Construct, Western Blot

    A, Immunofluorescent images of MCF10A cells from in situ proximity ligation assays using primary antibodies against EGFR and HER2 to assess co-localization. Cells are parental or overexpress exogenous cDNAs of EGFR WT, EGFR N361A, EGFR L858R, or a single construct containing two mutations EGFR N361A/L858R. Scale bar represents 50 μm. B, Representative quantification of mean pixel intensity of cellular regions defined by rhodamine Actin stain, including five replicate images per condition. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001, n = 5.
    Figure Legend Snippet: A, Immunofluorescent images of MCF10A cells from in situ proximity ligation assays using primary antibodies against EGFR and HER2 to assess co-localization. Cells are parental or overexpress exogenous cDNAs of EGFR WT, EGFR N361A, EGFR L858R, or a single construct containing two mutations EGFR N361A/L858R. Scale bar represents 50 μm. B, Representative quantification of mean pixel intensity of cellular regions defined by rhodamine Actin stain, including five replicate images per condition. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001, n = 5.

    Techniques Used: In Situ, Ligation, Construct, Staining

    A-B, Dose course of relative viability measured by CTG of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A after 72 hours of treatment with either (A) necitumumab or (B) osimertinib. ns = not significant, * p < 0.05; *** p < 0.001, n = 3.
    Figure Legend Snippet: A-B, Dose course of relative viability measured by CTG of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A after 72 hours of treatment with either (A) necitumumab or (B) osimertinib. ns = not significant, * p < 0.05; *** p < 0.001, n = 3.

    Techniques Used:



    Similar Products

    pbabe puro egfr wild-type  (Addgene inc)
    90
    Addgene inc pbabe puro egfr wild-type
    A, Diagram of domain architecture of <t>EGFR,</t> showing heterodimerization between EGFR and a binding partner such as Her2. Yellow star indicates approximate site of the common oncogenic L858 mutation, red star indicates approximate site of the N361 glycosylation site, green indicates ligands such as EGF or AREG that bind to EGFR to induce dimerization. B, Percentage of fluorescent cells from flow cytometry of MCF10A cells that were labeled with anti-EGFR antibody conjugated to Alexa-Fluor 488, or empty <t>puro-IRES-eGFP</t> vector as the stably fluorescent positive control which is not labeled by fluorescent antibody. Cells used were parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A. C, Representative immunofluorescent microscopy images of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A, stained for EGFR, vimentin, ATP1A1, or DAPI.
    Pbabe Puro Egfr Wild Type, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbabe puro egfr wild-type/product/Addgene inc
    Average 90 stars, based on 1 article reviews
    pbabe puro egfr wild-type - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    pbabe puro egfr wild type construct  (TaKaRa)
    86
    TaKaRa pbabe puro egfr wild type construct
    A, Diagram of domain architecture of <t>EGFR,</t> showing heterodimerization between EGFR and a binding partner such as Her2. Yellow star indicates approximate site of the common oncogenic L858 mutation, red star indicates approximate site of the N361 glycosylation site, green indicates ligands such as EGF or AREG that bind to EGFR to induce dimerization. B, Percentage of fluorescent cells from flow cytometry of MCF10A cells that were labeled with anti-EGFR antibody conjugated to Alexa-Fluor 488, or empty <t>puro-IRES-eGFP</t> vector as the stably fluorescent positive control which is not labeled by fluorescent antibody. Cells used were parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A. C, Representative immunofluorescent microscopy images of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A, stained for EGFR, vimentin, ATP1A1, or DAPI.
    Pbabe Puro Egfr Wild Type Construct, supplied by TaKaRa, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbabe puro egfr wild type construct/product/TaKaRa
    Average 86 stars, based on 1 article reviews
    pbabe puro egfr wild type construct - by Bioz Stars, 2026-02
    86/100 stars
    		  Buy from Supplier
    pbabe puro egfr wild type  (Addgene inc)
    93
    Addgene inc pbabe puro egfr wild type
    A, Diagram of domain architecture of <t>EGFR,</t> showing heterodimerization between EGFR and a binding partner such as Her2. Yellow star indicates approximate site of the common oncogenic L858 mutation, red star indicates approximate site of the N361 glycosylation site, green indicates ligands such as EGF or AREG that bind to EGFR to induce dimerization. B, Percentage of fluorescent cells from flow cytometry of MCF10A cells that were labeled with anti-EGFR antibody conjugated to Alexa-Fluor 488, or empty <t>puro-IRES-eGFP</t> vector as the stably fluorescent positive control which is not labeled by fluorescent antibody. Cells used were parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A. C, Representative immunofluorescent microscopy images of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A, stained for EGFR, vimentin, ATP1A1, or DAPI.
    Pbabe Puro Egfr Wild Type, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbabe puro egfr wild type/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    pbabe puro egfr wild type - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    A, Diagram of domain architecture of EGFR, showing heterodimerization between EGFR and a binding partner such as Her2. Yellow star indicates approximate site of the common oncogenic L858 mutation, red star indicates approximate site of the N361 glycosylation site, green indicates ligands such as EGF or AREG that bind to EGFR to induce dimerization. B, Percentage of fluorescent cells from flow cytometry of MCF10A cells that were labeled with anti-EGFR antibody conjugated to Alexa-Fluor 488, or empty puro-IRES-eGFP vector as the stably fluorescent positive control which is not labeled by fluorescent antibody. Cells used were parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A. C, Representative immunofluorescent microscopy images of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A, stained for EGFR, vimentin, ATP1A1, or DAPI.

    Journal: bioRxiv

    Article Title: Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function

    doi: 10.1101/2024.07.12.603279

    Figure Lengend Snippet: A, Diagram of domain architecture of EGFR, showing heterodimerization between EGFR and a binding partner such as Her2. Yellow star indicates approximate site of the common oncogenic L858 mutation, red star indicates approximate site of the N361 glycosylation site, green indicates ligands such as EGF or AREG that bind to EGFR to induce dimerization. B, Percentage of fluorescent cells from flow cytometry of MCF10A cells that were labeled with anti-EGFR antibody conjugated to Alexa-Fluor 488, or empty puro-IRES-eGFP vector as the stably fluorescent positive control which is not labeled by fluorescent antibody. Cells used were parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A. C, Representative immunofluorescent microscopy images of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A, stained for EGFR, vimentin, ATP1A1, or DAPI.

    Article Snippet: Introduction of N361A by site-directed mutagenesis on the pBABE puro EGFR wild-type (EGFR WT, RRID:Addgene_11011) and pBABE puro EGFR L858R (RRID:Addgene_11012) plasmids was performed by Azenta. pBABE puro IRES-eGFP (RRID:Addgene_14430).

    Techniques: Binding Assay, Mutagenesis, Glycoproteomics, Flow Cytometry, Labeling, Plasmid Preparation, Stable Transfection, Positive Control, Microscopy, Staining

    A, Time course of relative viability of in parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A, measured by Cell-Titer Glo luciferase assay (CTG) in stimulated media with 20 ng/mL of EGF. B, Dose course of relative viability of MCF10A cells overexpressing the indicated constructs after stimulation by EGF for 72 hours, measured by CTG. C, Dose course of relative viability of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A upon stimulation by AREG for 72 hours, both measured by CTG; ns = not significant, * p < 0.05; *** p < 0.001, n = 3; D, Immunoblots of whole cell lysates of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A stimulated with an additional 20 ng/mL of EGF for 15 minutes.

    Journal: bioRxiv

    Article Title: Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function

    doi: 10.1101/2024.07.12.603279

    Figure Lengend Snippet: A, Time course of relative viability of in parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A, measured by Cell-Titer Glo luciferase assay (CTG) in stimulated media with 20 ng/mL of EGF. B, Dose course of relative viability of MCF10A cells overexpressing the indicated constructs after stimulation by EGF for 72 hours, measured by CTG. C, Dose course of relative viability of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A upon stimulation by AREG for 72 hours, both measured by CTG; ns = not significant, * p < 0.05; *** p < 0.001, n = 3; D, Immunoblots of whole cell lysates of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A stimulated with an additional 20 ng/mL of EGF for 15 minutes.

    Article Snippet: Introduction of N361A by site-directed mutagenesis on the pBABE puro EGFR wild-type (EGFR WT, RRID:Addgene_11011) and pBABE puro EGFR L858R (RRID:Addgene_11012) plasmids was performed by Azenta. pBABE puro IRES-eGFP (RRID:Addgene_14430).

    Techniques: Luciferase, Construct, Western Blot

    A, Immunofluorescent images of MCF10A cells from in situ proximity ligation assays using primary antibodies against EGFR and HER2 to assess co-localization. Cells are parental or overexpress exogenous cDNAs of EGFR WT, EGFR N361A, EGFR L858R, or a single construct containing two mutations EGFR N361A/L858R. Scale bar represents 50 μm. B, Representative quantification of mean pixel intensity of cellular regions defined by rhodamine Actin stain, including five replicate images per condition. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001, n = 5.

    Journal: bioRxiv

    Article Title: Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function

    doi: 10.1101/2024.07.12.603279

    Figure Lengend Snippet: A, Immunofluorescent images of MCF10A cells from in situ proximity ligation assays using primary antibodies against EGFR and HER2 to assess co-localization. Cells are parental or overexpress exogenous cDNAs of EGFR WT, EGFR N361A, EGFR L858R, or a single construct containing two mutations EGFR N361A/L858R. Scale bar represents 50 μm. B, Representative quantification of mean pixel intensity of cellular regions defined by rhodamine Actin stain, including five replicate images per condition. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001, n = 5.

    Article Snippet: Introduction of N361A by site-directed mutagenesis on the pBABE puro EGFR wild-type (EGFR WT, RRID:Addgene_11011) and pBABE puro EGFR L858R (RRID:Addgene_11012) plasmids was performed by Azenta. pBABE puro IRES-eGFP (RRID:Addgene_14430).

    Techniques: In Situ, Ligation, Construct, Staining

    A-B, Dose course of relative viability measured by CTG of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A after 72 hours of treatment with either (A) necitumumab or (B) osimertinib. ns = not significant, * p < 0.05; *** p < 0.001, n = 3.

    Journal: bioRxiv

    Article Title: Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function

    doi: 10.1101/2024.07.12.603279

    Figure Lengend Snippet: A-B, Dose course of relative viability measured by CTG of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR WT or EGFR N361A after 72 hours of treatment with either (A) necitumumab or (B) osimertinib. ns = not significant, * p < 0.05; *** p < 0.001, n = 3.

    Article Snippet: Introduction of N361A by site-directed mutagenesis on the pBABE puro EGFR wild-type (EGFR WT, RRID:Addgene_11011) and pBABE puro EGFR L858R (RRID:Addgene_11012) plasmids was performed by Azenta. pBABE puro IRES-eGFP (RRID:Addgene_14430).

    Techniques: